Relias Media - Continuing Medical Education Publishing

The trusted source for

healthcare information and

CONTINUING EDUCATION.

  • Sign In
  • Sign Out
  • MyAHC
    • Home
      • Home
      • Newsletters
      • Blogs
      • Archives
      • CME/CE Map
      • Shop
    • Emergency
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Hospital
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Clinical
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • All Access
      • My Subscription
      • Subscribe Now
    • My Account
      • My Subscriptions
      • My Content
      • My Orders
      • My CME/CE
      • My Transcript
    Home » Ticagrelor, a New Antiplatelet Agent, Shows Promise in Secondary Prevention of Ischemic Stroke
    STROKE ALERT

    Ticagrelor, a New Antiplatelet Agent, Shows Promise in Secondary Prevention of Ischemic Stroke

    January 1, 2021
    No Comments
    Reprints
    Facebook Twitter Linkedin Share Share

    Related Articles

    Optimal Antiplatelet Therapy for Secondary Prevention of Ischemic Stroke

    Optimal Antiplatelet Therapy for Secondary Prevention of Ischemic Stroke

    Optimal Antiplatelet Therapy for Secondary Prevention of Ischemic Stroke

    Related Products

    Optimal Antiplatelet Therapy for Secondary Prevention of Ischemic Stroke

    Ticagrelor vs. Aspirin for Secondary Stroke Prevention — About the Same!

    Keywords

    stroke

    Atherosclerosis

    aspirin

    ticagrelor

    clopidogrel

    By Matthew E. Fink, MD

    Louis and Gertrude Feil Professor and Chair, Department of Neurology, Associate Dean for Clinical Affairs, New York Presbyterian/Weill Cornell Medical College

    Dr. Fink reports no financial relationships relevant to this field of study.

    SOURCE: Amerenco P, Denison H, Evans SR, et al. Ticagrelor added to aspirin in acute nonsevere ischemic stroke or transient ischemic attack of atherosclerotic origin. Stroke 2020;51:3504-3513.

    Ticagrelor is an antiplatelet agent that works by reversibly binding to P2Y12 adenosine diphosphate receptors on platelets, similar to the mechanism of action of clopidogrel. However, it is a direct-acting drug, and not a pro-drug, and does not need to be enzymatically converted to be active, like clopidogrel. Therefore, it is expected to be effective across a wider population than clopidogrel.

    In this double-blind study in patients with non-cardioembolic, non-severe ischemic stroke or transient ischemic attack (TIA), patients were randomized to receive ticagrelor with aspirin or placebo plus aspirin. In the ticagrelor group, patients received 180-mg loading dose on the first day followed by 90 mg twice daily for 30 days. The initial dose of aspirin was 300 mg to 325 mg on day 1 followed by 75 mg to 100 mg per day for 30 days. Treatment was started within 24 hours of symptom onset. The prespecified analysis evaluated stroke recurrence or death within 30 days. The groups were divided into those who had atherosclerosis of the appropriate carotid artery of at least 30% and those who had no significant atherosclerosis.

    A total of 11,016 patients were randomized, and 21.3% of them had ipsilateral atherosclerotic stenosis. After 30 days, the primary endpoint of stroke or death occurred in 8.1% of patients with ipsilateral stenosis randomized to ticagrelor, and in 10.9% randomized to placebo (hazard ratio [HR], 0.73; P = 0.023).

    In patients without ipsilateral stenosis, the primary event rate was 4.8% with ticagrelor and 5.4% with placebo, a nonsignificant difference. Severe bleeding occurred in 0.4% of patients with atherosclerosis treated with ticagrelor and 0.2% of patients with atherosclerosis treated with placebo. However, in the nonatherosclerotic patients, severe bleeding occurred in 0.5% of the ticagrelor patients and in 0.1% of the control group, a significant difference (HR, 5.87; P = 0.001).

    In patients with ipsilateral atherosclerosis and non-severe stroke or TIA, the combination of ticagrelor with aspirin appears to result in a lower rate of recurrent stroke or death at 30 days, compared to patients treated with aspirin alone.

    However, this is viewed as an exploratory analysis, and a larger Phase III trial is necessary for confirmation. A head-to-head trial with aspirin/clopidogrel would be informative as well. There is a significantly increased risk of severe bleeding with the use of ticagrelor and aspirin in combination.

    Post a comment to this article

    Report Abusive Comment

    www.reliasmedia.com

    Neurology Alert

    View PDF
    Neurology Alert (Vol. 40, No. 5) - January 2021
    January 1, 2021

    Table Of Contents

    Neurotropism of COVID-19: What Is New?

    Cranial Neuropathy in CIDP

    Rapid Eye Movement Sleep Duration Is Predictive of Life Expectancy

    Rhabdomyolysis Etiology

    Medical Therapy vs. Carotid Endarterectomy in Patients with Asymptomatic Carotid Stenosis

    Ticagrelor, a New Antiplatelet Agent, Shows Promise in Secondary Prevention of Ischemic Stroke

    A Mobile Interventional Stroke Team (MIST) Shows Promise in Performing Rapid Thrombectomy

    Begin Test

    Buy this Issue/Course

    Financial Disclosure: Neurology Alert’s Editor in Chief Matthew Fink, MD; Peer Reviewer M. Flint Beal, MD; Editorial Group Manager Leslie Coplin; Editor Jason Schneider; Executive Editor Shelly Morrow Mark; and Accreditations Director Amy M. Johnson, MSN, RN, CPN, report no financial relationships relevant to this field of study.

    Shop Now: Search Products

    • Subscription Publications
    • Books & Study Guides
    • Webinars
    • Group & Site
      Licenses
    • State CME/CE
      Requirements

    Webinars And Events

    View All Events
    • Home
      • Home
      • Newsletters
      • Blogs
      • Archives
      • CME/CE Map
      • Shop
    • Emergency
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Hospital
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Clinical
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • All Access
      • My Subscription
      • Subscribe Now
    • My Account
      • My Subscriptions
      • My Content
      • My Orders
      • My CME/CE
      • My Transcript
    • Help
    • Search
    • About Us
    • Sign In
    • Register
    Relias Media - Continuing Medical Education Publishing

    The trusted source for

    healthcare information and

    CONTINUING EDUCATION.

    Customer Service

    customerservice@reliasmedia.com

    U.S. and Canada: 1-800-688-2421 x 2

    International +1-404-262-5476 x 2

    Accounts Receivable

    1-800-688-2421 x 3
    ReliasMedia_AR@reliasmedia.com

    Sales

    1-800-688-2421 x 1

    Mailing Address

    • 1010 Sync St., Suite 100
      Morrisville, NC 27560-5468
      USA

    © 2022 Relias. All rights reserved.

    Do Not Sell My Personal Information  Privacy Policy  Terms of Use  Contact Us  Reprints  Group Sales

    For DSR inquiries or complaints, please reach out to Wes Vaux, Data Privacy Officer, DPO@relias.com

    Design, CMS, Hosting & Web Development :: ePublishing